Research programme: radioimmunoconjugate therapies - WILEX/Telix Pharmaceuticals

Drug Profile

Research programme: radioimmunoconjugate therapies - WILEX/Telix Pharmaceuticals

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Telix Pharmaceuticals; WILEX AG
  • Developer Telix Pharmaceuticals
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Jan 2017 Early research in Cancer in Australia (Parenteral) (Telix website, May 2017)
  • 16 Jan 2017 WILEX licenses girentuximab to Telix Pharmaceuticals for use with therapeutic radionuclides
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top